Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Monitoring patterns of care in mCRPC patients with the help of the Cancer Registry

ESMO 2016

7 - 11 Oct 2016

Published: 10 Oct 2016

Views: 2369

Rating:

Save

Dr Simon Chowdhury - Guy's Hospital, London, UK

Dr Chowdhury talks to ecancertv at ESMO 2016 about the Cancer Registry, that monitors the treatments and outcomes of over 3,000 patients across Europe with metastatic castration-resistant prostate cancer (mCRPC).

Dr Chowdhury also spoke with ecancer about fatigue among mCRPC patients treated with enzalutamide here.

Related Videos

Cancer in emergencies: What can we do better to protect the most vulnerable?

Prof Tezer Kutluk - Turkish Association for Cancer Research and Control, Ankara...

Cancer in emergencies: What can we do better to protect the most vulnerable? ( Prof Tezer Kutluk - Turkish Association for Cancer Research and Control, Ankara, Turkey )

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

OncoAlert Round Up for September 15-21, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for September 15-21, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

OncoAlert Round Up for August 25th - 31st, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 25th - 31st, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

War in Ukraine: The Global Medical Knowledge Alliance's response to improving...

Prof Richard Sullivan, Asst. Prof Darya Kizub and Asst. Prof Nelya Melnitchouk

War in Ukraine: The Global Medical Knowledge Alliance's response to improving cancer care ( Prof Richard Sullivan, Asst. Prof Darya Kizub and Asst. Prof Nelya Melnitchouk )

Latest in immunological technologies that can treat, control, and prevent cancer

Dr Jill O’Donnell-Tormey - Chief Executive Officer, Cancer Research Institute

Latest in immunological technologies that can treat, control, and prevent cancer ( Dr Jill O’Donnell-Tormey - Chief Executive Officer, Cancer Research Institute )

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?

Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru

Targeting BRAF V600E in metastatic colorectal cancer: where are we today? ( Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru )

Neo-adjuvant therapy for different cancers in the Philippines

Dr Priscilla Caguioa - St Luke's Medical Center, Manila, Philippines

Neo-adjuvant therapy for different cancers in the Philippines ( Dr Priscilla Caguioa - St Luke's Medical Center, Manila, Philippines )

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

More from ecancer